Sucralfate

Sucralfate (CAS No.: 54182-58-0) is a basic aluminum sucrose sulfate complex classified as a locally acting gastroprotective agent widely used in gastrointestinal research and drug discovery. It exerts its primary biological activity through inhibition of peptic enzymatic activity and selective binding to negatively charged subepithelial proteins exposed at sites of mucosal injury, leading to the formation of a viscous, adherent protective barrier that shields the vascular bed and proliferative zones from acid, bile salts, and proteolytic damage. This compound has been shown to suppress pepsin activity in both animal-derived and human gastric systems and to mitigate ulcer formation in multiple preclinical models, including chemically and surgically induced gastric injury, partly through modulation of luminal pH and reduction of hydrogen ion diffusion. Sucralfate functions primarily via physicochemical and barrier-forming mechanisms rather than classical receptor-mediated pathways, making it a useful tool for studying mucosal defense, epithelial repair processes, and gastrointestinal pharmacology. Quantitative in vitro potency metrics are not typically defined in terms of standard receptor-binding parameters, but functional inhibitory effects are generally observed across low micromolar to higher concentration ranges depending on assay conditions. In experimental settings, it is commonly applied in cell-based models of epithelial injury and in vivo models of gastric and duodenal ulceration, where dosing and exposure conditions are adjusted according to specific study designs aimed at evaluating mucosal protection, anti-ulcer activity, and interactions with other therapeutic agents.